Home > Authorities > Institutes > Record #144984 |
W010
Klinische StudienzentraleID | I:(DE-He78)W010-20160331 |
All known publications ...
Download: BibTeX | EndNote XML, Text | RIS |
Journal Article
Rationale and design of the PAMSARC (pasireotide as maintenance treatment with monthly deep intramuscular injection in SSTR2/3/5-expressing synovial sarcoma and desmoplastic small round cell tumor) multicenter phase 2 trial.
Cancer treatment and research communications 45, 100986 (2025) [10.1016/j.ctarc.2025.100986]
BibTeX |
EndNote:
XML,
Text |
RIS
Journal Article
Molecularly matched targeted therapies plus radiotherapy in glioblastoma: the phase 1/2a N2M2 umbrella trial.
Nature medicine nn, nn (2025) [10.1038/s41591-025-03928-9]
BibTeX |
EndNote:
XML,
Text |
RIS
Journal Article (Erratum/Correction)
Author Correction: Risk of hematological malignancies from CT radiation exposure in children, adolescents and young adults.
Nature medicine 31(7), 2452 (2025) [10.1038/s41591-025-03689-5]
BibTeX |
EndNote:
XML,
Text |
RIS
Journal Article
Die Entwicklung eines neuen Impfstoffs gegen humane Papillomviren (HPV) im akademischen Umfeld – TEIL 2 / Papillomavirus Impfstoff PANHPVAX:First-in-Human – eine neue Herausforderung
PM/QM - Fachzeitschrift für pharmazeutische Medizin und Qualitätsmanagement - nur für Mitglieder 1, 46-54 (2025)
BibTeX |
EndNote:
XML,
Text |
RIS
Journal Article
Venetoclax-based salvage therapy as bridge-to-transplant is feasible and effective in patients with relapsed/refractory AML.
Blood advances 9(2), 375-385 (2025) [10.1182/bloodadvances.2024013086]
Files
BibTeX |
EndNote:
XML,
Text |
RIS
Journal Article
Die Entwicklung eines neuen Impfstoffs gegen humane Papillomviren (HPV) im akademischen Umfeld – TEIL 1 Papillomavirus Impfstoff PANHPVAX: Herausfordernde Schritte von der Idee zur Erstanwendungsstudie
PM/QM - Fachzeitschrift für pharmazeutische Medizin und Qualitätsmanagement - nur für Mitglieder 26(3), 4-11 (2024)
BibTeX |
EndNote:
XML,
Text |
RIS
Journal Article (Letter)
Randomized phase III GnG study on two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and double-blinded intensive postremission therapy with or without glasdegib in patients with newly diagnosed acute myeloid leukemia.
Haematologica 109(6), 1973-1976 (2024) [10.3324/haematol.2023.284346]
Fulltext by Pubmed Central
BibTeX |
EndNote:
XML,
Text |
RIS
Journal Article (Letter)
Genetics as predictive marker for consolidation therapy with high-dose cytarabine in acute myeloid leukemia.
Haematologica 109(6), 1629 - 1630 (2024) [10.3324/haematol.2024.285624]
BibTeX |
EndNote:
XML,
Text |
RIS
Journal Article
Late-onset NPM1 mutation in a MYC-amplified relapsed / refractory acute myeloid leukemia patient treated with gemtuzumab ozogamicin and glasdegib.
Haematologica 109(11), 3811-3815 (2024) [10.3324/haematol.2023.284922]
BibTeX |
EndNote:
XML,
Text |
RIS
Journal Article
Impact of inotuzumab ozogamicin on outcome in relapsed or refractory acute B-cell lymphoblastic leukemia patients prior to allogeneic hematopoietic stem cell transplantation and risk of sinusoidal obstruction syndrome/venous occlusive disease
Haematologica 109(5), 1385–1392 (2024) [10.3324/haematol.2023.284310]
BibTeX |
EndNote:
XML,
Text |
RIS
All known publications ...
Download: BibTeX | EndNote XML, Text | RIS |